Walleye Capital LLC Lowers Stock Holdings in Immatics (NASDAQ:IMTX)

Walleye Capital LLC cut its holdings in shares of Immatics (NASDAQ:IMTX - Free Report) by 32.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 282,193 shares of the company's stock after selling 137,200 shares during the quarter. Walleye Capital LLC owned about 0.24% of Immatics worth $3,220,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of IMTX. Perceptive Advisors LLC boosted its holdings in Immatics by 76.5% during the 2nd quarter. Perceptive Advisors LLC now owns 8,086,159 shares of the company's stock valued at $93,961,000 after acquiring an additional 3,503,750 shares during the period. Frazier Life Sciences Management L.P. purchased a new position in shares of Immatics in the 2nd quarter valued at about $13,392,000. TD Asset Management Inc boosted its stake in shares of Immatics by 11.8% in the 2nd quarter. TD Asset Management Inc now owns 357,526 shares of the company's stock valued at $4,154,000 after buying an additional 37,770 shares during the period. abrdn plc purchased a new position in shares of Immatics in the 3rd quarter valued at about $2,657,000. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Immatics in the 2nd quarter valued at about $2,404,000. 64.41% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

IMTX has been the subject of several recent research reports. Cantor Fitzgerald reiterated an "overweight" rating on shares of Immatics in a research note on Thursday, September 5th. Bank of America cut their target price on Immatics from $16.00 to $15.00 and set a "buy" rating on the stock in a research report on Tuesday, November 19th. The Goldman Sachs Group raised Immatics to a "strong-buy" rating in a research report on Monday, November 25th. Finally, Piper Sandler began coverage on Immatics in a research report on Monday, October 7th. They set an "overweight" rating and a $19.00 target price on the stock. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $16.67.

Immatics Stock Down 3.1 %

IMTX traded down $0.26 during trading on Tuesday, hitting $8.06. 300,289 shares of the stock were exchanged, compared to its average volume of 626,561. The firm has a market capitalization of $962.04 million, a P/E ratio of -12.21 and a beta of 0.74. Immatics has a 1-year low of $7.46 and a 1-year high of $13.77. The stock has a fifty day moving average price of $9.33 and a two-hundred day moving average price of $11.01.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.